202
Participants
Start Date
December 31, 2016
Primary Completion Date
October 31, 2021
Study Completion Date
January 31, 2023
GOLIMUMAB
Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
CHU LIEGE - Sart Tilman, Liège
Caen Unversity Hospital, Caen
CHU de Nimes- Hopital Carémeau, Nîmes
CHU de TOULOUSE, Toulouse
CHU Bordeaux- Hopital Haut Levèque, Pessac
CHU de Montpellier- Hopital saint Eloi, Montpellier
CHU de Tours - Hopital Trousseau, Tours
CHU de Saint Etienne- Hopital Nord, Saint-Priest-en-Jarez
CHU NANTES - Hôpital Hôtel Dieu, Nantes
CHU NANCY - Hopital Brabois, Vandœuvre-lès-Nancy
CHU Clermont Ferrand, Clermont-Ferrand
Chu Strasbourg, Strasbourg
CHU de Colmar- Hopital Trousseau Medecine A, Colmar
CHU LYON- Hopital Lyon Sud, Pierre-Bénite
APHP- Hopital BICHAT, Paris
CHU Amiens, Amiens
APHP- Hopital BEAUJON, Clichy
CHU Dinant Godinne UCL Namur, Namur
Chu Besancon, Besançon
CHRU Lille, Lille
Chu Reims, Reims
CHU RENNES - Hopital Pontchaillou, Rennes
CHU de NICE- Hopital Archet 2, Nice
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
OTHER